Send to

Choose Destination
See comment in PubMed Commons below
Diagn Microbiol Infect Dis. 1994 Jan;18(1):61-8.

Antimicrobial activity of a new antipseudomonal dual-action drug, Ro 25-0534.

Author information

  • 1Anti-Infectives Research Center, University of Iowa College of Medicine, Iowa City 52242.


Ro 25-0534, a tertiary amine-linked dual action combination (DAC) of a catechol cephalosporin and ciprofloxacin, was compared with a previously described DAC (Ro 23-9424), ciprofloxacin and cefotaxime. A total of 688 recent clinical isolates were tested and an additional collection of 110 Gram-negative bacilli possessing documented resistance to broad-spectrum antimicrobials were used. Ro 25-0534 was active against all tested species of Enterobacteriaceae (MIC90 range, 0.06-2 micrograms/ml), oxacillin-susceptible staphylococci, beta-hemolytic streptococci, and penicillin-susceptible pneumococci (MIC90 range, 1-2 micrograms/ml). Haemophilus influenzae (MIC90 range, 0.25-0.5 micrograms/ml), Moraxella catarrhalis (MIC90, 0.5 microgram/ml), and most nonenteric Gram-negative bacilli (MIC90 range, 2-4 micrograms/ml) such as Pseudomonas aeruginosa, Acinetobacter spp., and Xanthomonas maltophilia. Enterococci and Bacteroides fragilis isolates were resistant to Ro 25-0534. The Ro 25-0354 potency against most susceptible strains was generally severalfold less than that of Ro 23-9424 (except for Pseudomonas-Xanthomonas) or ciprofloxacin alone.

[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science
    Loading ...
    Write to the Help Desk